Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The ViiV Healthcare grants are a key element of the company’s Risk to Reason HIV initiative guided by and for Black women.
Held in Puerto Rico, #2022USCHA highlighted HIV in Latino populations, language justice, storytelling, music and much more.
Gilead, ViiV, NMAC, HRC, NBJC, GLAAD and others offer $5.5 million in grants to help community groups respond to monkeypox.
Generic cabotegravir, an every-other-month injectable to prevent HIV, will arrive in select countries. WHO and Health Gap have opinions.
Cultural influencers take off their blindfolds to destigmatize HIV prevention in ViiV’s “Me in You, You in Me” campaign. [VIDEOS]
ViiV Healthcare’s Risk to Reasons initiative offers stigma-free language for discussing HIV and Black women. Apply now for grants.
The Women as the Face of AIDS Summit, organized by Iris House, also honored three trailblazing women working to end the HIV epidemic.
The approval makes this the first single-pill regimen containing dolutegravir available in a water-dispersible formulation.
Using the new dosing schedule, injectable cabotegravir and rilpivirine can be administered just six times a year.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.
A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.
After years of taking daily oral cabotegravir and Edurant, people with suppressed HIV switched to long-acting injectable Cabenuva.
Nine key insights from over 760 interviews for ViiV Healthcare’s “Here as I Am” report.
A global study examined how outcomes improve when physicians engage their HIV-positive patients in joint decision-making.
A clinical trial compared injectable cabotegravir given every eight weeks versus daily Truvada for HIV prevention.
Bonus: Your donations to the Broadway Cares effort Emergency Grants for Pandemic Relief will be matched by Gilead Sciences.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.